Tarsus Pharmaceuticals, Inc. (TARS): Shareholders' Equity
$343.43M
As of 2025-12-31
$346.73M
As of 2026-06-30
+21.2%
3-year compound annual growth
+15.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $343.43M | +53.0% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $224.53M | +14.0% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $196.99M | +2.1% | 2026-02-23, Balance as of period end |
| 2022-12-31 | $192.90M | +15.7% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $166.73M | +0.5% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $165.98M | n/m | 2022-03-14, Balance as of period end |
| 2019-12-31 | -$6.00M | n/m | 2021-03-31, Balance as of period end |
| 2018-12-31 | -$1.35M | n/a | 2021-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $343.43M | +53.0% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $477.32M | +36.8% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $472.96M | +0.1% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $218.79M | +7.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $698.58M | -1.7% |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗